Comparison of Nadolol, A New Long-Acting Beta-Receptor Blocking Agent, and Placebo in the Treatment of Stable Angina Pectoris
Authors:
- William ShapiroWSWilliam Shapiro
- Janet ParkJPJanet Park
- Robert DiBiancoRDRobert DiBianco
- Steven N. SinghSSSteven N. Singh
- Richard J. KatzRKRichard J. Katz
- Ross FletcherRFRoss Fletcher
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Exercise testing in men with significant left main coronary disease.Heart, 1979
- Angina Pectoris and the Placebo EffectNew England Journal of Medicine, 1979
- Angina Pectoris: Effective Therapy Once DailyJournal of International Medical Research, 1979
- Comparative effect of nadolol and propranolol on exercise tolerance in patients with angina pectoris.Heart, 1978
- Testing antianginal therapy: in favor of current practiceAmerican Heart Journal, 1978
- Efficacy of propranolol in the control of exercise-induced or augmented ventricular ectopic activity.Circulation, 1978
- Comparison of the new beta-adrenoceptor antagonist, nadolol, and propranolol in the treatment of angina pectorisCurrent Medical Research and Opinion, 1978
- Pharmacology of nadolol (SQ 11725), a β-adrenergic antagonist lacking direct myocardial depressionEuropean Journal of Pharmacology, 1975
- ??-Adrenergic Receptor Blocking Drugs in Angina PectorisDrugs, 1974
- Exercise stress testing in evaluation of patients with ischemic heart diseaseProgress in Cardiovascular Diseases, 1969